Genenta Science S.p.A. Stock (NASDAQ:GNTA)


OwnershipFinancialsChart

Previous Close

$4.80

52W Range

$2.20 - $7.28

50D Avg

$4.84

200D Avg

$4.00

Market Cap

$85.85M

Avg Vol (3M)

$13.76K

Beta

0.74

Div Yield

-

GNTA Company Profile


Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Yes

Country

IT

Employees

14

IPO Date

Dec 15, 2021

Website

GNTA Performance


GNTA Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income---
Net Income---
EBITDA---
Basic EPS---
Diluted EPS---

Fiscal year ends in Dec 23 | Currency in EUR

Peer Comparison


TickerCompany
CYTCyteir Therapeutics, Inc.
PMVPPMV Pharmaceuticals, Inc.
MLYSMineralys Therapeutics, Inc.
AVTEAerovate Therapeutics, Inc.
CSBRChampions Oncology, Inc.
JANXJanux Therapeutics, Inc.
ANTXAN2 Therapeutics, Inc.
MNOVMediciNova, Inc.
PHVSPharvaris N.V.
RZLTRezolute, Inc.
PEPGPepGen Inc.
ANEBAnebulo Pharmaceuticals, Inc.
ADAGAdagene Inc.
MOLNMolecular Partners AG
PRDSPardes Biosciences, Inc.
OPTOpthea Limited
ELYMEliem Therapeutics, Inc.